知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.05 seconds)

    Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
    11.
    发明授权
    Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment 有权
    用于预测未接受他汀类药物治疗的冠状动脉疾病患者的心血管结局的脂质体生物标志物

    公开(公告)号：US09052328B2

    公开(公告)日：2015-06-09

    申请号：US14356594

    申请日：2012-11-07

    Applicant: Zora Biosciences OY

    Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

    IPC: G01N33/92

    CPC classification number: G01N33/92 ,  G01N2570/00 ,  G01N2800/042 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/70

    Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

    Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。

    Ceramides and their use in diagnosing CVD
    12.
    发明授权
    Ceramides and their use in diagnosing CVD 有权

    公开(公告)号：US11474116B2

    公开(公告)日：2022-10-18

    申请号：US16218363

    申请日：2018-12-12

    Applicant: ZORA BIOSCIENCES OY

    Inventor： Reijo Laaksonen

    IPC: G01N33/92 ,  A61K31/164 ,  C07B59/00

    Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.

    Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients
    13.
    发明申请
    Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients 有权

    公开(公告)号：US20210239719A1

    公开(公告)日：2021-08-05

    申请号：US17177503

    申请日：2021-02-17

    Applicant: ZORA BIOSCIENCES OY

    Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

    IPC: G01N33/92

    Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

    Use of ceramides and LPLs in diagnosing CVD
    14.
    发明授权
    Use of ceramides and LPLs in diagnosing CVD 有权

    公开(公告)号：US10184932B2

    公开(公告)日：2019-01-22

    申请号：US15371661

    申请日：2016-12-07

    Applicant: ZORA BIOSCIENCES, OY

    Inventor： Mika Hilvo ,  Reini Hurme ,  Reijo Laaksonen ,  Virve Vaeisaenen

    IPC: G01N33/49 ,  G01N33/92

    Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.

    LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT
    20.
    发明申请
    LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT 有权
    用于预防冠状动脉疾病患者心脏病变的不良生物标志物不能接受治疗

    公开(公告)号：US20140295467A1

    公开(公告)日：2014-10-02

    申请号：US14356594

    申请日：2012-11-07

    Applicant: ZORA BIOSCIENCES OY

    Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

    IPC: G01N33/92

    CPC classification number: G01N33/92 ,  G01N2570/00 ,  G01N2800/042 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/70

    Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

    Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。

Patent Agency Ranking